#### Kindred Biosciences, Inc. Form 3 December 11, 2013 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0104

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Veszpremi Ervin			<ol> <li>Date of Event Requiring Statement (Month/Day/Year)</li> </ol>	<sup>g</sup> 3. Issuer Name and Ticker or Trading Symbol Kindred Biosciences, Inc. [KIN]					
(Last) C/O KINDI			12/11/2013	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)		Filed(Month/Day/Year)	ıal		
INC., 1499 BAYSHORE HIGHWAY, SUITE 226 (Street)				X_ Director 10% Owner Officer Other (give title below) (specify below)			2		
BURLINGAME, CA 94010			_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person	-					
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Beneficially Owned						
1.Title of Secu (Instr. 4)	rity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Reminder: Rep owned directly	or indirectly.		ch class of securities benefic		SEC 1473 (7-02	2)			
	Perso	ons who res	pond to the collection of						

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security       2. Date Exercisable and         (Instr. 4)       Expiration Date         (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

January 31,

2005

0.5

Expires:

response...

Estimated average burden hours per

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (right to buy) $(1)$	(2)	02/04/2023	Common Stock	40,000	\$ 0.32	D	Â
Stock Option (right to buy) $\frac{(1)}{2}$	(3)	08/29/2023	Common Stock	20,000	\$ 1.37	D	Â

## **Reporting Owners**

	Relationships					
<b>Reporting Owner Name / Address</b>	Director	10% Owner	Officer	Other		
Veszpremi Ervin C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME, CA 94010	ÂX	Â	Â	Â		
Signatures						
/s/ Ervin 12/11/2013						

Veszpremi <u>\*\*</u>Signature of

Date

Reporting Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Granted pursuant to the Issuer's 2012 Equity Incentive Plan
- (2) 10,000 of the shares subject to the option will vest on January 1, 2014, with the remaining shares vesting in equal monthly installments over the ensuing 36 months, subject to the Reporting Person's continuous service as a director.
- (3) 5,000 of the shares subject to the option will vest on August 29, 2014, with the remaining shares vesting in equal monthly installments over the ensuing 36 months, subject to the Reporting Person's continuous service as a director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.